ADARx Pharmaceuticals
Signal active
Organization
Contact Information
Overview
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precisely target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Medical
Founded
2019
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
ADARx Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $26.6B in funding across 80 round(s). With a team of 11-50 employees, ADARx Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - ADARx Pharmaceuticals, raised $200.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
16
Lead Investors
0
Total Funding Amount
$332.0M
Details
4
ADARx Pharmaceuticals has raised a total of $332.0M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Seed | 5.0M | ||
| 2021 | Early Stage Venture | 75.0M | ||
| 2023 | Early Stage Venture | 46.0M | ||
| 2023 | Late Stage Venture | 200.0M |
Investors
ADARx Pharmaceuticals is funded by 40 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| SR One | - | FUNDING ROUND - SR One | 200.0M |
| Ricky Sun | - | FUNDING ROUND - Ricky Sun | 200.0M |
| ADARx Pharmaceuticals | - | FUNDING ROUND - ADARx Pharmaceuticals | 200.0M |
| Bain Capital Life Sciences | - | FUNDING ROUND - Bain Capital Life Sciences | 200.0M |
Recent Activity
There is no recent news or activity for this profile.